DEC 15, 2020 7:05 AM PST

New combination therapy may help patients with treatment resistance

New research from scientists at the UCLA Jonsson Comprehensive Cancer Center showcases a novel combination therapy that could help cancer patients who have developed resistance to certain treatments. The combination therapy, which is described in the journal Cancer Discovery, holds potential for treating BRAF mutated melanoma as well as subtypes of melanoma, lung, pancreatic and colon cancers with RAS or NF1 mutations.

Conventional therapies that target the MAPK cancer pathway are limited in that they only work on cancers that have certain mutations in the BRAF cancer gene. Even in these cases, patients often experience treatment resistance and tumor recurrence is a concern for many patients. This research aimed to suppress the MAPK pathway in a unique way.

"The idea behind this study was to develop a combination treatment that helps people with common lethal cancers by eliciting durable anti-tumor responses," said senior author Roger Lo, MD, PhD, who is a professor of medicine at the David Geffen School of Medicine at UCLA. "Right now, MEK inhibitors by themselves provide limited clinical benefits, and the current MAPK pathway-targeted, combination therapy can help only certain patients with cancers harboring specific BRAF mutations."

To address this, the research team considered how a combination therapy of a MEK inhibitor and a second-generation RAF inhibitor (known as MEKi and type II RAFi) could treat cancer more effectively and deter resistance. They tested this combination on models of melanoma, non-small cell lung cancer, pancreatic cancer and colon cancer.

Photo: Pixabay

"It is quite remarkable that two drugs were able to bind to each of two proteins and sequester them from further propagating signals inside the cancer cells," said co-senior author Gatien Moriceau, PhD, who is an assistant adjunct professor at the David Geffen School of Medicine at UCLA. "The combination unexpectedly preserves killer T-cells inside the tumors, which allows them to hunt down drug-resistant tumor clones. This favorable impact on T-cells paves the way to combine MAPK-targeted therapies with anti-PD-1/L1 immune checkpoint therapy."

The combination therapy is now being tested in clinical trials for melanoma and non-small cell lung cancer.

Sources: Cancer Discovery, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 18, 2021
Cancer
Cancer cell lines are too dissimilar from human cancer cells
JUN 18, 2021
Cancer cell lines are too dissimilar from human cancer cells
A new study finds cultured cancer cells lack genetic similarity to humans. This is concerning because cancer cell lines ...
JUN 23, 2021
Cancer
Military universal health system boasts higher survival rates for colon cancer patients
JUN 23, 2021
Military universal health system boasts higher survival rates for colon cancer patients
New results published in the American Association for Cancer Research journal Cancer Epidemiology, Biomarkers & Prev ...
AUG 01, 2021
Genetics & Genomics
Rethinking the Cause of Mutations That Lead to Melanoma
AUG 01, 2021
Rethinking the Cause of Mutations That Lead to Melanoma
Throughout our lives, new cells often replace the ones that become damaged or worn out. As cells divide, they have to re ...
AUG 07, 2021
Cancer
New Drug Combo Eliminates Pancreatic Cancer in Mice
AUG 07, 2021
New Drug Combo Eliminates Pancreatic Cancer in Mice
A combination of three immunotherapy drugs can eliminate pancreatic tumors in mice. The study was published in Canc ...
AUG 18, 2021
Cell & Molecular Biology
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
AUG 18, 2021
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
For many years, researchers have studied how an enzyme called APOBEC3 can help protect the body from pathogenic viruses, ...
OCT 10, 2021
Cell & Molecular Biology
DNA Can Reveal Treatments for Lung Cancer in 'Never-Smoked' Patients
OCT 10, 2021
DNA Can Reveal Treatments for Lung Cancer in 'Never-Smoked' Patients
There is a well-known causal connection between smoking and lung cancer, and most research on lung cancer has been focus ...
Loading Comments...